Analyzing the whole-blood expression signature of four growth factor-related genes (ARAF, BRAF, KRAS, and RAF-1) and four genes involved in metabolism (ATP6V1H, OAZ2, PANK2, and PLD3), combined with tumor grade, they were able to predict the efficacy of PRRT with an accuracy of 95% [39]. The gene discussed is OAZ2; the disease is neoplasm.